Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Company Presentation Date & Time: Monday, September 14, 2026, 2:00 p.m. EDT

Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 14-16, 2026
Fireside Chat Date & Time: Wednesday, September 16, 2026, 1:05 p.m. EDT

A live audio webcast of the Morgan Stanley fireside chat will be available at https://cc.webcasts.com/morg007/091426a_js/?entity=125_OG1TMTP, and on the Events Calendar of the Investors section of the Company's website, www.protalix.com. An archived replay will be available following the event.

For more information or to schedule a one-on-one meeting with management, please contact your conference representative.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are available in multiple markets. These recombinant therapeutic proteins are expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. Protalix's global partner for Elfabrio® (pegunigalsidase alfa-iwxj), approved for Fabry disease in the United States, the European Union, and additional markets, is Chiesi Global Rare Diseases. Elelyso® (taliglucerase alfa) for Gaucher disease is approved in 23 markets and partnered with Pfizer Inc. worldwide, with the exception of Brazil, where Protalix partners with Fundação Oswaldo Cruz, an arm of the Brazilian Ministry of Health. Protalix's development portfolio includes PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, currently in the Phase 2 RELEASE trial; PRX-119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases; and research programs in rare renal diseases. To learn more, please visit www.protalix.com.

For Investor Inquiries:

Mike Moyer, Managing Director
LifeSci Advisors, LLC
Phone: (617) 308-4306
[email protected]

SOURCE Protalix BioTherapeutics, Inc.